Skip to main content
OpenTrials
Completed

NCT Number: NCT04425317

Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients

Recently, the world was shaken awake by a pandemic caused by a novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). In most nations drastic isolation measures were taken to minimize the further spread of the Coronavirus Disease 2019 (COVID-19). Being the first pandemic sparked by a Coronavirus, little was known on COVID-19 and its implications on general health. Our understanding on the virus and its potential effects on health is growing. In Belgium, the situation is stabilizing, and doctors and healthcare workers are slowly recommencing routine work and consultations. As also fertility treatments were abruptly interrupted, many patients are in need to resume their treatment. The limited evidence of SARS-CoV-2 on pregnancy seems to be rather satisfying1, but practically nothing is known about the possible impact of an active SARS-CoV-2 infection on female gametes. Viral transmission occurs predominantly through respiratory droplets, but transmission to gametes cannot be ruled out.

Since the onset of the pandemic, knowledge about the molecular details of SARS-CoV-2 infection rapidly grew. Coronaviruses are enveloped RNA viruses. For a virus to deliver their genome into the host cell, attachment and entrance into that cell is a crucial step. The coronavirus surface protein spike (S) mediates entry into target cells by binding to a cellular receptor and subsequent fusing of the viral envelope with a host cell membrane. The SARS-CoV-2-S protein (SARS-S) utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for host cell entry. Host proteases such as transmembrane serine protease 2 (TMPRSS2) are then needed to cleave the viral S protein, allow-ing permanent fusion of the viral and host cell membranes2. Expression of ACE2 and TMPRSS2 has been shown in testicular, uterine and placental cells. Based on available transcriptomic data, co-expression of ACE2 and TMPRSS2 is also seen on oocyte level, but the possible impact on reproduction is unknown. The BSG (basigin or CD147), a receptor on host cells, was also identified as a possible route for viral invasion.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Uz Brussels

Brussels, 1090, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female
  • Undergoing IVF/ICSI treatment
  • Planned for an oocyte retrieval
  • PCR positive of SARS-CoV-2 or high suspicion for COVID 19 based on CT scan
  • Signed informed consent

Exclusion criteria

  • None

Treatment and study plan

Blood sample

Diagnostic Test

Blood sample and endometrial biopsy on the moment of oocyte retrieval

Other names: Endometrial biopsy

Primary outcomes

  1. Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium

    Time frame: 1 day

    Identification of viral RNA in cumulus-oocyte-complexes, exclusively looking at the material that is considered waste material in a normal oocyte retrieval

Secondary outcomes

  1. Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium

    Time frame: 1 day

    Presence of receptors, identified as possible steps in the entry pathway for SARS-CoV-2

Sponsors and collaborators

Lead sponsor

CRG UZ Brussel

Other

Registry information

Official study title

Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment

Acronym: COVID_OFF

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
Jun 11, 2020
Registry last updated
Feb 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.